OKYO Pharma (OKYO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OKYO OKYO Pharma

Watchlist

1.030
+0.030+3.00%

Close Oct 3 16:00 ET

34.85MMarket Cap-1807P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

OKYO Pharma Analyst Ratings
BenzingaAug 27 12:37 ET · Ratings
Buy Rating on OKYO Pharma: U.S. Patent and Strong Trial Results for OK-101 Boosts Market Potential
TipRanksAug 27 11:55 ET · Ratings
Express News | OKYO Pharma Secures US Patent Covering OK-101's Potential To Treat Symptoms Of Dry Eye Disease
BenzingaAug 27 07:01 ET
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
BenzingaAug 26 05:58 ET
OKYO Pharma CEO Interview to Air on Bloomberg TV
GlobeNewswireAug 23 09:00 ET
Tonix TNXP Mpox Publication; OKYO Pharma OKYO Chairman Acquires Shares
BioPharmCatalystAug 23 08:16 ET

Comments

Jaguar8

Aug 27 06:04

NEWS

$OKYO Pharma (OKYO.US)$
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated ...

Trytosaveabit

Aug 27 06:04

News

$OKYO Pharma (OKYO.US)$ OKYO Pharma Secures US Patent Covering OK-101's Potential To Treat Symptoms Of Dry Eye Disease
Benzinga· 2 mins ago

Trytosaveabit

Aug 23 06:23

This may be why? New filing a bit ago

$OKYO Pharma (OKYO.US)$ announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.